Clinical Trials
243 trialsTherapy for Children With Advanced Stage Neuroblastoma
St. Jude Children's Research Hospital
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
National Cancer Institute (NCI)
Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors
Roswell Park Cancer Institute
Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
National Institutes of Health Clinical Center (CC)
Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma
Memorial Sloan Kettering Cancer Center
MIBG With Dinutuximab +/- Vorinostat
New Approaches to Neuroblastoma Therapy Consortium
Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer
University of Washington
UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma
Ultimovacs ASA
UV1/hTERT2012P
Ultimovacs ASA
UV1-hTERT2012L
Ultimovacs ASA
Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma
Ultimovacs ASA
WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)
Sellas Life Sciences Group
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
Sellas Life Sciences Group
WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation
Sellas Life Sciences Group
WOKVAC
University of Washington
Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence
Case Comprehensive Cancer Center
Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)
National Heart, Lung, and Blood Institute (NHLBI)
Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma
Fundació Sant Joan de Déu
Vaccine Therapy in Treating Patients With Multiple Myeloma
National Cancer Institute (NCI)
Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma
National Cancer Institute (NCI)
Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Stage III or Stage IV Non-Hodgkin's Lymphoma
University of Nebraska
HER3+
Cancer Insight, LLC
Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer
National Cancer Institute (NCI)
Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma
National Cancer Institute (NCI)
Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant
University of Nebraska
Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
Ludwig Institute for Cancer Research
Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
University of Nebraska
Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia
Eastern Cooperative Oncology Group
Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma
Eastern Cooperative Oncology Group
Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia
Eastern Cooperative Oncology Group
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Eastern Cooperative Oncology Group
Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission
Eastern Cooperative Oncology Group
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia
Eastern Cooperative Oncology Group
BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer
Barbara Ann Karmanos Cancer Institute
Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors
Mayo Clinic
Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma
National Institutes of Health Clinical Center (CC)
Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis
Virginia Commonwealth University
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
National Cancer Institute (NCI)
Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas
Ludwig Institute for Cancer Research
Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia
Roswell Park Cancer Institute
Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Roswell Park Cancer Institute
Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity
Gliknik Inc.
The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate Cancer
University of Colorado, Denver
Pembrolizumab and GM-CSF in Biliary Cancer
University of California, San Francisco
A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma
National Institute of Allergy and Infectious Diseases (NIAID)
A Phase I Study of the Combination of Recombinant GM-CSF, AZT, and Chemotherapy (ABV) (Adriamycin, Bleomycin, Vincristine) in AIDS and Kaposi's Sarcoma
National Institute of Allergy and Infectious Diseases (NIAID)
Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma
National Institute of Allergy and Infectious Diseases (NIAID)
A Phase I Trial of Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor (rHuGM-CSF), Recombinant Alpha Interferon and Azidothymidine (AZT) in AIDS-Associated Kaposi's Sarcoma
National Institute of Allergy and Infectious Diseases (NIAID)
GM-CSF Mouthwash for Preventing and Treating Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer
University of California, San Francisco